Compare BridgeBio Pharma Inc (BBIO) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Workiva Inc — how do they compare? BridgeBio Pharma Inc trades at $82.33 (market cap $16.46B), while Workiva Inc trades at $54.24 (market cap $3.01B). The key difference: BridgeBio Pharma Inc is far larger — about 5.5× Workiva Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | WK | |
|---|---|---|
Market Cap | $16.46B | $3.01B |
Sector | Health | Technology |
52-Week High | $90.17 | $93.31 |
52-Week Low | $44.81 | $44.31 |
Enterprise Value | $18.02B | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Workiva (WK) trades at $54.54, up 4.54% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q1 2026 EPS of $0.77 exceeding expectations. Revenue growth remains solid at $884.57 million for 2025, projected to reach $926 million in 2026. Technical indicators show bullish moving averages while RSI levels suggest potential overbought conditions near-term.
Workiva presents a compelling growth story with 88.9% analyst buy ratings and a $71 consensus price target offering 30% upside. However, elevated valuation multiples (P/E 223.71, EV/EBITDA 71.73) and thin net margins (1.53%) warrant caution. Key risks include competitive pressures in compliance software and execution challenges in maintaining growth momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
